
Claims:

1. A compound of formula (I)




(I)

wherein

X represents hydrogen or hydroxyl and

Y represents one of the following groups:



in free base or acid addition salt form.

2. (4S,5R)-4-[5-(1H-Indol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane .

3. 5-{2-[(4S,5R)-(1-Aza-bicyclo[3.3.1]non-4-yl)oxy]-pyrimidin-5-yl}-1,3-dihydro-indol-2-one.

4. (4S,5R)-4-[6-(1H-Indol-5-yl)-pyridin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane .


5. (4S,5R)-4-[5-(1H-Indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane .

6. (4S,5R)-4-[6-(1H-Indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane .

7. 5-{6-[(4S,5R)-(1-Aza-bicyclo[3.3.1]non-4-yl)oxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one.


8. A process for preparation of a compound of formula (I) comprising the steps of

i) reacting a compound of formula (IX)



(IX)

wherein Y is as defined above and z represents a leaving group with a compound of formula (X)




(X)

where R represents H , C_1-C_4alkyl or both RO represent together with the B to which they are attached a heterocyclic moiety, X is as defined above, and

ii) recovering the so obtained compound of formula (I).


9. A process for preparation of a compound of formula (I) comprising the steps of

i) reacting a compound of formula (XI)



(XI)

with a compound of formula (XII)



(XII)

wherein X and Y are as defined above and PG is a suitable protecting group,

ii) subsequent deprotection of the so obtained compound and

iii) recovering the so obtained compound of formula (I) in free base or acid addition salt form.

10. The compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

11. The compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the prevention, treatment and / or delay of progression of psychotic and neurodegenerative disorders.

12. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

13. The use of a compound of claims 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the prevention and the treatment of psychotic and neurodegenerative disorders.


14. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the prevention, treatment and / or delay of progression of psychotic and neurodegenerative disorders.

15. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the prevention, treatment and / or delay of progression of a disease or condition in which nAChR α7 activation plays a role or is implicated.

16. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the prevention, treatment and / or delay of progression of a disease or condition in which nAChR α7 activation plays a role or is implicated.

Claims


1. A compound of formula (I)



(I)

wherein

X represents hydrogen or hydroxyl and
Y represents one of the following groups:



in free base or acid addition salt form, wherein said compound is selected from the group consisting of
(4S,5R)-4-[5-(1H-Indol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane,
5-{2-[(4S,5R)-(1-Aza-bicyclo[3.3.1]non-4-yl)oxy]-pyrimidin-5-yl}-1,3-dihydro-indol-2-one,
(4S,5R)-4-[6-(1H-Indol-5-yl)-pyridin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane,
(4S,5R)-4-[5-(1H-Indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane,
(4S,5R)-4-[6-(1H-Indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane, and
5-{6-[(4S,5R)-(1-Aza-bicyclo[3.3.1]non-4-yl)oxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one.

2. A compound of formula (I) according to claim 1, wherein said compound is (4S,5R)-4-[5-(1H-Indol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane.

3. A compound of formula (I) according to claim 1, wherein said compound is 5-{2-[(4S,5R)-(1-Aza-bicyclo[3.3.1]non-4-yl)oxy]-pyrimidin-5-yl}-1,3-dihydro-indol-2-one.

4. A compound of formula (I) according to claim 1, wherein said compound is (4S,5R)-4-[6-(1H-Indol-5-yl)-pyridin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane.


5. A compound of formula (I) according to claim 1, wherein said compound is (4S,5R)-4-[5-(1H-Indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane.

6. A compound of formula (I) according to claim 1, wherein said compound is (4S,5R)-4-[6-(1H-Indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane.

7. A compound of formula (I) according to claim 1, wherein said compound is 5-{6-[(4S,5R)-(1-Aza-bicyclo[3.3.1]non-4-yl)oxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one.


8. A process for preparation of a compound of formula (I) according to claim 1 comprising the steps of

i) reacting a compound of formula (IX)



(IX)

wherein Y is as defined above and z represents a leaving group with a compound of formula (X)




(X)

where R represents H, C_1-C_4alkyl or both RO represent together with the B to which they are attached a heterocyclic moiety, X is as defined above, and
ii) recovering the so obtained compound of formula (I).


9. A process for preparation of a compound of formula (I) according to claim 1 comprising the steps of

i) reacting a compound of formula (XI)



(XI)

with a compound of formula (XII)



(XII)

wherein X and Y are as defined above and PG is a suitable protecting group,
ii) subsequent deprotection of the so obtained compound and
iii) recovering the so obtained compound of formula (I) in free base or acid addition salt form.

10. The compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

11. The compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the prevention, treatment and / or delay of progression of psychotic and neurodegenerative disorders.

12. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

13. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the prevention, treatment and / or delay of progression of psychotic and neurodegenerative disorders.

14. A combination comprising a therapeutically effective amount of a compound of claim 1 and/or a pharmaceutically acceptable salt thereof, and a second Pharmaceutical active compound and/or a pharmaceutically acceptable salt thereof.